Abstract 302P
Background
DNA repair pathways are implicated both in carcinogenesis and progression of cancer. The genetically determined baseline expression level of DNA repair genes is associated with risk of cervical pre-cancer and cancer. In this study, we aim to evaluate expression level of one such DNA repair gene -Excision Repair Cross- Complementation Group 4 (ERCC4) and its correlation to various clinical and pathological parameters in cervical cancer in North Indian population.
Methods
Expression profiling of ERCC4 in 55 histopathologically confirmed cervical tumor biopsies and 25 control samples (hysterectomy) were done using Real time PCR(q-PCR), western blot analysis. Correlation analysis was done with different clinical and pathological parameters. ROC curve assessment was done to check the diagnostic utilities of the calculated data. One way ANOVA and t-test were used to calculate statistical significance using Graphpad PRISM 9.
Results
Relative fold change for mRNA expression analysis showed up-regulation of ERCC4 in 78.2% (n=43) patient biopsies, calculated by ΔΔct method. At translational level, the up regulation was around 52% (n=28). The up-regulations were significant with p value less than 0.05. Also, ERCC4, mRNA expression showed positive correlation with tumor stage and grade. Positive correlation was also observed in ERCC4 protein expression with respect to different age groups and histological status. High risk HPV-18 strain type was shown to be more influential in up regulating ERCC4 expression, both at transcriptional and translational level.
Conclusions
ERCC4 is significantly up-regulated at both transcriptional and translational levels in cervical cancer patient cohort, comprising of North Indian population. Higher expression of ERCC4 in tumor samples suggests its role as a potential diagnostic and/or prognostic marker in Ca Cervix.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Medical Sciences, BHU, Varanasi, India.
Funding
BHU under Institute of Eminence (IoE).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract